DIABETES CARE IN THE UK

The First UK Injection Technique Recommendations
2nd Edition

optimising injection technique in diabetes
The Forum for Injection Technique (FIT) was developed to establish and promote best practice in injection technique for all involved in diabetes care and the founding members are experienced diabetes specialist nurses.

These recommendations aim to raise awareness of existing and emerging research relating to injection technique and the impact this may have on health outcomes for those with diabetes that require subcutaneous injection therapy.

FIT was established following the 3rd International Injection Technique meeting (Athens 2009). From this meeting a consensus was reached to establish the international injection technique recommendations. Following a very successful inaugural symposium held in London on 4th June 2010, attended by over 40 experienced diabetes specialist nurses from across the United Kingdom (UK) and Ireland, the international injection technique recommendations have been adapted for use in the UK.

These are the first UK recommendations for Injection Technique and these will be revised on an annual basis to include new research evidence as it emerges.

FIT is an autonomous organisation whose overarching mission is to support people with diabetes using injectable therapies to achieve the best possible health outcomes that can be influenced by correct injection technique. There are now nearly 3 million people in the UK with diabetes and of these approximately 800,000 are on injectable therapies.*

The development of FIT and the subsequent UK recommendations for injection technique have been supported by BD Europe and endorsed by the pharmaceutical companies whose therapies include subcutaneous injections of insulin and GLP-1 agonists.

FIT is committed to supporting the implementation of the recommendations by all those involved in diabetes care and to developing the recommendations further. We welcome any comments, suggestions and active participation in ensuring that the recommendations remain relevant and useful for now and the future.

Debbie Hicks
Nurse Consultant – Diabetes (Chair)

Fiona Kirkland
Nurse Consultant – Diabetes

Julia Pledger
Nurse Consultant – Diabetes

Su Down
Nurse Consultant – Diabetes

* data on file

DATE PUBLISHED: OCTOBER 2011
A Scientific Advisory Board (Athens 2009) lead the review of available evidence and decided that for the strength of a recommendation the following scale would be used:

- **STRONGLY RECOMMENDED**
- **RECOMMENDED**
- **UNRESOLVED ISSUE**

For the scientific support the following scale was used.

1. At least one randomised controlled study
2. At least one non-randomised (or non-controlled or epidemiologic) study
3. Consensus expert opinion based on extensive patient experience.

Thus each recommendation is followed by both a letter and number (i.e. A2). The letter indicates the weight a recommendation should have in daily practice and the number, its degree of support in the medical literature. The most relevant publications bearing on a recommendation are also cited. There are comparably few randomised clinical trials in the field of injection technique (compared, for example, with blood pressure control) so judgements such as ‘strongly recommended’ versus ‘recommended’ are based on a combination of the weight of clinical evidence, the implications for patient therapy and the judgement of the group of experts.

These recommendations apply to the majority of people with diabetes using injectable therapy, but there will inevitably be individual exceptions for which these rules must be adjusted.

The New Injection Recommendations for Patients with Diabetes: Diabetes & Metabolism 2010. Vol 36. informed these recommendations and we thank the editors of Diabetes & Metabolism for permission to use material from this article.
Diabetes UK both welcomes and supports the FIT initiative. Good injection technique leads to good blood glucose control which is vital in preventing the long term complications of diabetes. As so many people with diabetes are now being prescribed injectable medication, this is a timely and important enterprise which will bring great benefit to them.

SIMON O’NEILL, DIRECTOR OF CARE, INFORMATION AND ADVOCACY. DIABETES UK

Advances in the treatment of diabetes have led to an increase in the number of injectable therapies available. Correct technique is of paramount importance in order to ensure the benefits of injectable therapies such as insulin and GLP-1s. The Forum for Injectable Therapy (FIT) provides comprehensive evidenced based guidelines to improve the process and education of self injection technique for people with diabetes. As a company committed to improving the care of patients with diabetes, Lilly UK welcomes the FIT initiative as an important step in supporting diabetes care in the United Kingdom.

IAN DANE, SENIOR DIRECTOR, ELI LILLY & COMPANY

Novo Nordisk fully endorse the FIT initiative. The benefits of modern injectable medications for the treatment of diabetes can only be fully realised through the use of correct injection technique. Novo Nordisk believe it is imperative that Healthcare Professionals understand the importance of good injection technique and convey this to people with diabetes under their care. FIT is a superb initiative, from leading professionals in the diabetes care, which will make a big difference in this area.

JOHN DAWBER, MARKETING DIRECTOR, NOVO NORDISK LTD.

sanofi-aventis are a company who strive to improve the care for people with diabetes who are using insulin therapy by producing a range of insulins. We are proud to support the FIT (Forum for Injection Technique) initiative which is aiming to improve current practice through demonstration of best practice and the sharing of scientific evidence. We, too, appreciate the importance of good injection technique in ensuring people with diabetes who are using insulin therapy achieve the most benefit from their medication and wish FIT every success. We look forward to working with FIT in the future.

JASON BROWN, DIABETES BRAND LEAD, SANOFI-AVENTIS
1.0 Psychological Challenges of Injections

1.1 Children

1 Children have a lower threshold for pain than adults and sometimes find injecting uncomfortable. The Healthcare Professional (HCP) should ask about pain, since many young people with diabetes will not bring it up spontaneously. (18, 20) A 2

2 Younger children may be helped by distraction techniques (as long as they do not involve trickery) or play therapy (e.g. injecting into a stuffed animal) while older children may respond better to Cognitive Behavioural Therapies (CBT) where available. (19) A 2

3 CBT includes relaxation training, guided imagery, graded exposure, active behavioural rehearsal, modelling and reinforcement as well as incentive scheduling. (19) A 2

1.2 Adults

1 The HCP should prepare all people with type 2 diabetes for likely future injectable therapy early in the disease pathway, by explaining the natural, progressive nature of the disease, stating that it includes injectable therapy and making clear that injectable therapy treatment is not a sign of patient failure. (30) A 2

2 Both the short-term and long-term advantages of good glucose management should be emphasised. Finding the right combination of therapies including injectables leading to good glucose management should be the goal. (31,32) A 2

3 Through culturally-appropriate pictures and stories, HCPs should show how injectable therapy could enhance both the duration and quality of life. (31) A 2

4 HCPs should reflect on their own perceptions of injectable therapy and avoid using any terms which imply that such therapy is a sign of failure, a form of punishment or a threat. (33,34) A 3

5 Pen devices may have psychological advantages over syringes and therefore maybe more acceptable. (31,35-37) A 2

At least one randomised controlled study
At least one non-randomised (or non-controlled or epidemiologic) study
Consensus expert opinion based on extensive patient experience.
2.0 Therapeutic Education

Adult

1. The HCP should spend time exploring the individual’s anxieties about the injecting process and the injectable therapy itself. (33,40) A 3

2. At the beginning of injection therapy (and at least every year thereafter) the HCP should discuss:
   - Injecting regimen
   - Choice and management of the devices used
   - Choice, care and self-examination of injection sites
   - Correct injection techniques (including site rotation, injection angle and possible use of skin folds)
   - Injection complications and how to avoid them
   - Optimal needle length
   - Safe disposal of used sharps (32-35, 38-41)

   Ensure that each of these topics have been fully understood. (34) A 3

3. Injection technique education should be put in place and regularly reviewed and recorded in the individual’s care plan. A 3

4. Current injection practice should be discussed and if possible observed. Injection sites should be examined and palpated, if possible at each visit but at least once a year. (38,40,41) A 3
3.0 Injection Sites

The diagram shows the current recommended injection sites for injectable therapy

4.0 Injection Site Care

1. The site should be inspected and palpated by the individual prior to injection. (5,6) A 3

2. Avoid using a site showing signs of lipohypertrophy, inflammation, oedema or infection until the problem has been resolved. (15,49,50-55) A 2

3. Injections should be given into a clean site using clean hands. (56) A 2

4. The site should be cleansed with soap and water when found to be unclean. (56) A 3

5. Disinfection of the site is usually not required; however, alcohol swabs may be used prior to injections given in the hospital or care home setting. (6, 57-60) C 2
5.0 Insulin Storage and Suspension

1. Store injectable medication in current use at room temperature (for a maximum of one month after initial use, and within expiry date). Avoid direct sunlight and areas of temperature extremes. Store unopened injectable medication in an area of the refrigerator where freezing is unlikely to occur. (66,67) A 2

2. Cloudy insulin (e.g. NPH and pre-mixed insulin) must be gently rolled ten times and inverted ten times (not shaken) until the crystals go back into suspension and the solution becomes milky white. (61-65) A 2

6.0 Injecting Process

Tips for making injections less painful include:

- Keeping injectable therapy in use, at room temperature (66,67) A 2

- Using needles of shorter length and smaller diameter (157) A 1

- Using a new needle at each injection (5,6,17,36,68) A 2

- Insert the needle in a quick smooth movement through the skin (69) A 3

- Inject slowly and ensure that the plunger (syringe) or thumb button (pen) has been fully depressed (69) A 3

- If using alcohol swabs, inject only when the alcohol has fully dried B 3
7.0
The Correct Use of Pen Devices

1 Pen devices should be primed (observing at least a drop at the needle tip) according to the manufacturer’s instructions before each injection. Once flow is verified, the desired dose should be dialled and the injection administered. (36,68) A 3

2 Pen devices and cartridges are for single person use only and should never be shared due to the risk of cross contamination. (37,57) A 2

3 Pen needles should be used only once. (3,5,6,17,59,76,77) A 2

4 Using a new needle each time may reduce the risk of needle breakage in the skin, ‘clogging’ of the needle, inaccurate dosing and indirect costs (e.g Abscess). (77) B 2

5 After pushing the thumb button in completely, the individual should count slowly for 10 seconds before withdrawing the needle in order to deliver the full dose and prevent the leakage of medication. Counting past 10 seconds may be necessary for higher doses. (61,69,71,74,78,79) A 1

6 Needles should be safely disposed of immediately after use and not left attached to the pen. This prevents the entry of air (or other contaminants) into the cartridge as well as the leakage of medication out of the cartridge, which can affect subsequent dose accuracy. (71-75) A 2

7 Injecting through clothing should be discouraged. As needle lengths are becoming shorter there is increased risk of intradermal injection. B 3

8.0
The Correct Use of Syringes

1 A syringe should be used only once and disposed of safely. (3,5,6,17,59,76,77) A 2

2 When drawing up insulin, the air equivalent to the dose should be drawn up first and injected into the vial to facilitate easier withdrawal. A 3

3 If air bubbles are seen in the syringe, hold syringe with needle uppermost, tap the barrel to bring them to the top and then remove the bubbles by pushing the plunger to expel the air. A 2
9.1 Human Insulin

1 IM injection of all human insulin should be avoided since rapid absorption and serious hypoglycaemia can result. \( (95,96) \)

2 The thigh and buttocks are the preferred injection sites when using NPH (intermediate acting) as the basal insulin, since absorption is slowest from these sites. \( (43,97) \)

3 The abdomen is the preferred site for soluble human insulin, since absorption is fastest there. \( (16,44,46,98-100) \)

4 The absorption of soluble (short acting) human insulin in the elderly can be slow and this insulin should not be used when a rapid effect is needed. \( (14,101) \) (Note: Insulin actions may overlap)

5 For those people who require very large doses of insulin U-500 insulin maybe an option instead of U-100. U-500 is only available as soluble insulin. However it has a pharmacokinetic profile more closely simulating NPH human intermediary insulin than soluble short acting human. U-100. \( (5,6,158) \)

6 Massaging the site before or after injection may speed up absorption and is not generally recommended. \( (5,6,70) \)

9.2 Premixed Insulin

1 Premixed insulin (human or analogue) should be given in the abdomen in the morning to increase the speed of absorption of the short-acting insulin in order to cover post-breakfast glycaemic excursions. \( (12) \)

2 Premixed insulin should be given in the thigh or buttock before evening meal as this leads to slower absorption and decreases the risk of nocturnal hypoglycaemia. \( (93,97) \)

3 Massaging the site before or after injection may speed up absorption and is not generally recommended. \( (5,6,70) \)
9.0 Absorption Rates Continued

9.3 Insulin Analogues

1 **Rapid-acting** insulin analogues may be given at any of the injection sites, as absorption rates do not appear to be site-specific. (81-85) A 1

2 **Rapid-acting** analogues should not be given intramuscularly (IM). (82,83,86) A 2

3 **Long-acting** insulin analogues may be given at any of the injection sites, as absorption rates do not appear to be site-specific. (87,88) B 2

4 IM injections of **long-acting** analogues must be avoided due to the risk of severe hypoglycaemia or erratic control. (89,90) A 1

5 When injecting **rapid and long acting** analogue insulin these should be given in different sites even if given at different times during the day. B 3

6 Larger doses may cause a delay in the peak and increase the duration of action. (5,6) B 3

7 Massaging the site before or after injection may speed up absorption and is not generally recommended. (5,6,70) C 3

9.4 GLP-1 Agonists

1 Pending further studies, people with diabetes who inject GLP-1 agents (e.g. exenatide - Byetta®; liraglutide - Victoza®) should follow the manufacturers instructions. (72) A 2
10.0 Needle Length

10.1 Children and Adolescents

1 There is no clinical reason for recommending needles longer than 6mm for children and adolescents. (118) A 2

2 Children and adolescents using a 5/6mm needle should lift a skin fold with each injection. (9,83,86,110,112-117,156,157) A 1

3 In the majority of cases a 4mm needle may be inserted at 90 degrees without a lifted skin fold. (9) A 1

4 If children have only an 8 mm needle available (as is currently the case with syringe users), it is essential to use a lifted skin fold or give injections into the buttocks. (111,118,119) A 1

5 Arms should only be used for injections if administered by a third party and using a lifted skin fold. A 3

6 Avoid pushing the pen device in to the skin thus indenting the skin during the injection, as the needle may penetrate deeper than intended and enter the muscle. B 3

10.2 Adults

1 There is no clinical reason for recommending needles longer than 8mm. (105,119,132) A 2

2 4, 5 and 6 mm needles are suitable for all people with diabetes regardless of BMI; they may not require a lifted skin fold; particularly if using 4 mm needles. (9,74,104,106 – 108,156,157) A 1

3 Injections with shorter needles (4, 5, 6 mm) should be given in adults at 90 degrees to the skin surface. (9,74,106 – 108,130) A 1

4 To prevent possible IM injections when injecting into slim limbs and abdomens, even with short needles (4,5 and 6mm) may warrant use of a lifted skin fold. (9, 105, 106,131) A 2

5 Individuals using >8mm needles should ensure they are using a lifted skin fold to avoid IM injections. (105,131) A 2
11.0
Lifted Skin Folds

1 All people with diabetes/carers should be taught the correct technique for lifting a skin fold from the onset of injectable therapy. (see Fig 2.)

2 The lifted skin fold should not be squeezed so tightly that it causes skin blanching or pain.

3 The optimal sequence should be:
   1) Make a lifted skin fold
   2) Insert needle into skin at 90° angle (see Figure 3)
   3) Administer therapy
   4) Leave the needle in the skin for at least 10 seconds after the thumb button plunger is fully depressed
   5) Withdraw needle from the skin
   6) Release lifted skin fold
   7) Dispose of used needle safely (see section 17)

Figure 2: Correct (left) and incorrect (right) ways of performing the skin fold.

Figure 3: The correct angle of injection when lifting a skin fold is 90°
12.0 Lipohypertrophy

1 Sites should be inspected and any abnormalities documented by the HCP within the individual’s care plan. At a minimum, each site should be examined annually (preferably at each visit for children). If lipohypertrophy is already present the sites should be monitored at every review. (41,138)

2 Individuals should be taught to examine their own injection sites and how to detect lipohypertrophy. (41,138)

3 Using various available tools such as making two ink marks at opposite edges of the lipohypertrophy allows the lipo to be measured and its size recorded for long-term follow up. If visible the area of lipohypertrophy could also be photographed for the same purpose. (41,138)

4 Individuals should be advised (and rationale explained) not to inject into areas of lipohypertrophy until abnormal tissue returns to normal (which can take months to years). (139,140)

5 Switching injections from areas of lipohypertrophy to normal tissue often requires a decrease of the dose of insulin injected. The amount of change varies from one individual to another and should be guided by frequent blood glucose measurements. (50,140)

6 Caution is needed; too great a reduction in dose could lead to an increased risk of Diabetic Ketoacidosis in people with Type 1 Diabetes. However, too small a reduction could result in hypoglycaemia. (136,137,139,141-143)

7 The best current preventative and therapeutic strategies for lipohypertrophy include rotation of injection sites with each injection, and non-reuse of needles. (136,137,139,141-143)

Lipoatrophy, although very rare, is a wasting of the subcutaneous tissue at injection sites. Injecting into these sites should be avoided.
13.0 Rotation of Injecting Sites

1 Individuals should be taught an easy-to-follow rotation scheme from the onset of injection therapy. (146,147) A 2

2 One scheme with proven effectiveness involves dividing the injection site into quadrants (or halves when using the thighs or buttocks); using one quadrant per week and moving always in the same direction, either clockwise or anti-clockwise (see Figures 4 and 5). (148) A 3

3 Injections within any quadrant or half should be spaced at least 1cm from each other in order to avoid repeat tissue trauma. A 3

4 HCP should verify that the rotation scheme is being followed at each visit and should provide advice where needed. A 3

5 Use a variation of educational approaches and available tools to inform how to detect for lipohypertrophy. A 3
14.0 Bleeding and Bruising

1. Individuals should be reassured that bleeding and bruising do not appear to have adverse clinical consequences for the absorption or action of injectable therapies. (149,150)  

2. If persistent bruising occurs review injection technique.  

15.0 Pregnancy

1. Pregnant women with diabetes (of any type) who continue to inject into the abdomen should give all injections using a raised skin fold. (151) 

2. Massaging the site before or after injection may speed up absorption and is not generally recommended. (5,6,70)  

16.0 Safety Issues

1. Under no circumstances should any HCP re-sheath needles, therefore either syringes or safety needles should be used. (153) 

2. Any HCP who is required to use a lifted skin fold must exhibit caution to avoid needle stick injury.
17.0
Disposal of injecting material

1 All HCPs and individuals/carers should be aware of local regulations regarding sharps disposal. HCPs individuals/carers should be made aware of the consequences of inappropriate disposal of sharps (e.g. needle stick injuries to others such as refuse workers). (154) A 3

2 Correct disposal should be taught to people with diabetes from the beginning of injection therapy and reinforced throughout. A 3

3 Where available, a needle clipping device could be used. It can be carried in the injection kit. A 3

4 Sharps guard (sharps box) is available on FP1o. However, disposal is according to local policy. B 3

5 Under no circumstance should sharps material be disposed of into the public rubbish or household refuse system. A 3

6 Empty pen devices can be disposed of in the normal household refuse when the needle is removed. B 3

A STRONGLY RECOMMENDED
B RECOMMENDED
C UNRESOLVED ISSUE

1 At least one randomised controlled study
2 At least one non-randomised (or non-controlled or epidemiologic) study
3 Consensus expert opinion based on extensive patient experience.
References


83 Frid A. Fat thickness and injectable therapy administration, what do we know? Insufsystems International 2006;5:17-19.
94 Chen JYV, Christiansen JS, Lauritzen T. Limitation to subcutaneous injectable therapy administration in type 1 diabetes. Diabetes, Obesity and Metabolism 2003;5:223-233.


107 Van Doorn LG, Albarda A, Lytzen L. Injectable therapy leakage and pain perception with NovoFine 6 mm and NovoFine 12 mm needle lengths in people with diabetes with type 1 or type 2 diabetes. Diabetic Medicine 1998;15:965-971.


Contributors

JACKIE STEDMAN  
SUE GREENHALGH  
MARY TRIMBLE  
ANGELA COOK  
CLAIRE BUSHNALL  
MEL GRAY  
GAYNOR HARRISON  
ANNA MARIA WISHER  
DEBORAH BROWN  
KAREN JONES  
CHARLOTTE SIMPSON  
JULIA BUNDOCK  
LINDA GOLDIE  
CLAIRE VICK  
CAROL SELLER  
RAZIA AMIN  
HILARY WHITTY  
LISA CLARKE  
VICKY WHITE  
ELLIE HANKS  
LIZ KAMPS  
JEAN DUFFELL  
ERICA FIGUIERIE  
LEANNE JENKINS  
SAIJI ROY  
DEVENADAN RAMKHELAWON  
SURIAYA KOHLIL  
INEZ WALKER

STEPHANIE SHAW  
ROSALEEN MCHUGH  
KAREN DANIELS  
CATHY BROOKER  
JUDITH NELSON  
NICOLA HEATH  
VAL BALL  
HAILEY BENNETT  
VICKY BUCZAK  
NORA COLLINS  
JO LEOW  
VALERIE DAWKINS  
GILLIAN BOAST  
JAYNE REED  
JUNE WALLACE  
HELEN ATKINS  
JAKKI BERRY  
PAM GILBY  
AMY BARRIDGE  
MARY TRIMBLE  
LINDA CLAPHAM  
JUDE CAMPBELL  
REBECCA THOMPSON  
CHRISTINE DOWLING  
NICOLA JACKSON  
MANI BASI  
SHEILA BURMISTON
DEBBIE HICKS  debbie.hicks@enfield.nhs.uk
FIONA KIRKLAND  Fiona.Kirkland@nhs.net
JULIA PLEDGER  Julia.Pledger@bedfordhospital.nhs.uk
SU DOWN  Su.Down@sompar.nhs.uk